Investors & Media
News
Sage Therapeutics to Present at American Academy of Neurology 2017 Annual Meeting
Below is the schedule for the presentations:
Date:
Poster Presentation Time:
Location: Poster Hall, Neighborhood A
Poster
Number: P3.008
Title: The pharmacokinetics of SAGE-217
in Phase 1 SAD and MAD studies
Date:
Poster Presentation Time:
Location: Poster Hall, Neighborhood A
Poster
Number: P3.009
Title: Next-generation neuroactive
steroid SAGE-217 in a multiple-ascending dose study
Date:
Poster Presentation Time:
Location: Poster Hall, Neighborhood G
Poster
Number: P3.224
Title: Evaluation of the costs, length of
stay, and mortality associated with super-refractory status epilepticus
in
Date:
Poster Presentation Time:
Location: Poster Hall, Neighborhood A
Poster
Number: P5.021
Title: Preclinical characterization of
SAGE-217 in a rodent model of oral dyskinesia
Date:
Poster Presentation Time:
Location: Poster Hall, Neighborhood A
Poster
Number: P6.017
Title: Next-generation neuroactive
steroid SAGE-217 in a single-ascending dose study
Date:
Poster Presentation Time:
Location: Poster Hall, Neighborhood B
Poster
Number: P6.068
Title: Preclinical pharmacology and
pharmacodynamic interactions of SAGE-547: Relevance to super-refractory
status epilepticus (SRSE)
Date:
Poster Presentation Time:
Location: Poster Hall, Neighborhood G
Poster
Number: P6.234
Title: Hemodynamic properties of SAGE-547
in patients with super-refractory status epilepticus: results from a
Phase 1/2 clinical trial
Date:
Poster Presentation Time:
Location: Poster Hall, Neighborhood G
Poster
Number: P6.241
Title: Pharmacokinetics of SAGE-547 in
patients with super-refractory status epilepticus
About
View source version on businesswire.com: http://www.businesswire.com/news/home/20170419005287/en/
Investor Contact:
paul.cox@sagerx.com
or
Media
Contact:
maureen.suda@sagerx.com
Source:
News Provided by Acquire Media